Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2007; 132(25/26): 1404-1406
DOI: 10.1055/s-2007-982044
DOI: 10.1055/s-2007-982044
Klinischer Fortschritt | Commentary
© Georg Thieme Verlag KG Stuttgart · New York
Klinische Immunologie 2007
Clinical immunology 2007Further Information
Publication History
eingereicht: 14.5.2007
akzeptiert: 24.5.2007
Publication Date:
15 June 2007 (online)

Was ist neu?
-
SLE: systemische B-Zelldepletion
-
Rheumatoide Arthritis: neue Biologika
-
Multiple Sklerose: Blockade der Lymphozytenmigration
Literatur
- 1
Breedveld F C, Weisman M H, Kavanaugh A F. et al .
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination
therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab
alone in patients with early, aggressive rheumatoid arthritis who had not had previous
methotrexate treatment.
Arthritis Rheum.
2006;
54
26-37
MissingFormLabel
- 2
Cohen S B, Emery P, Greenwald M W. et al .
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:
Results of a multicenter, randomized, double-blind, placebo-controlled, phase III
trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum.
2006;
54
2793-2806
MissingFormLabel
- 3
Dorner T, Kaufmann J, Wegener W A, Teoh N, Goldenberg D M, Burmester G R.
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy
of systemic lupus erythematosus.
Arthritis Res Ther.
2006;
8
R74
MissingFormLabel
- 4
Freim Wahl S G, Folvik M R, Torp S H.
Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission
after treatment with cytostatics and rituximab: case report and review of the literature.
Clin Neuropathol.
2007;
26
68-73
MissingFormLabel
- 5
Genovese M C, Cohen S, Moreland L. et al .
Combination therapy with etanercept and anakinra in the treatment of patients with
rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
Arthritis Rheum.
2004;
50
1412-1419
MissingFormLabel
- 6
Goekoop-Ruiterman Y P, Vries-Bouwstra J K, Allaart C F. et al .
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
Ann Intern Med.
2007;
146
406-415
MissingFormLabel
- 7
Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson S H, Henriksson E W, van Vollenhoven R F.
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant
proliferative lupus nephritis.
Arthritis Rheum.
2007;
56
1263-1272
MissingFormLabel
- 8
Kappos L, Antel J, Comi G. et al .
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med.
2006;
355
1124-1140
MissingFormLabel
- 9
Kappos L, Bates D, Hartung H P. et al .
Natalizumab treatment for multiple sclerosis: recommendations for patient selection
and monitoring.
Lancet Neurol.
2007;
6
431-441
MissingFormLabel
- 10
Kremer J M, Genant H K, Moreland L W. et al .
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis:
a randomized trial.
Ann Intern Med.
2006;
144
865-876
MissingFormLabel
- 11
Nishimoto N, Hashimoto J, Miyasaka N. et al .
Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor
(SAMURAI): - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded
Randomized Controlled Trial of Tocilizumab.
Ann Rheum Dis.
2007;
, May 7; [Epub ahead of print]
MissingFormLabel
- 12
Schiff M H, Burmester G R, Kent J D. et al .
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing
surveillance of patients with rheumatoid arthritis.
Ann Rheum Dis.
2006;
65
889-894
MissingFormLabel
- 13
Suntharalingam G, Perry M R, Ward S. et al .
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med.
2006;
355
1018-1028
MissingFormLabel
- 14
Taylor R P, Lindorfer M A.
Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune
complex decoy hypothesis.
Nat Clin Pract Rheumatol.
2007;
3
86-95
MissingFormLabel
- 15
Tokunaga M, Saito K, Kawabata D. et al .
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving
the central nervous system.
Ann Rheum Dis.
2007;
66
470-475
MissingFormLabel
- 16
Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, Gonzalez-Amaro R.
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory
to conventional therapy: a pilot study.
Arthritis Res Ther.
2006;
8
R83
MissingFormLabel
- 17
Weinblatt M, Schiff M, Goldman A. et al .
Selective costimulation modulation using abatacept in patients with active rheumatoid
arthritis while receiving etanercept: a randomised clinical trial.
Ann Rheum Dis.
2007;
66
228-234
MissingFormLabel
- 18
Weinblatt M E, Keystone E C, Furst D E, Kavanaugh A F, Chartash E K, Segurado O G.
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid
arthritis: ARMADA 4 year extended study.
Ann Rheum Dis.
2006;
65
753-759
MissingFormLabel
Prof. Dr. Georg M. N. Behrens
Prof. Dr. Reinhold E. Schmidt
Abteilung Klinische Immunologie und Rheumatologie, Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
Phone: 0511/5325713
Fax: 0511/5325324
Email: behrens.georg@mh-hannover.de